This is a Phase 1, open label, fixed sequence, 2 period study conducted in patients with solid tumors or lymphomas. The duration of participation in this study will be up to approximately 38 days not including screening, after which patients will be allowed to continue receiving enzastaurin. There is no planned duration for the extension phase of this study; patients will be allowed to continue to receive enzastaurin until fulfilling one of the criteria for discontinuation, such as unacceptable toxicity or disease progression.